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Lymphocytes from cystic fibrosis (CF) patients secrete less interferon-g (IFN-g) upon stimulation compared to controls. Expression of
interleukin (IL)-18 as an IFN-g inducing factor and of IL-10 as an IL-18 inhibiting factor were determined in bronchoalveolar lavage (BAL)
cells from CF patients (n = 5) and from normal control subjects (n = 9) as well as in peripheral blood mononuclear cells (PBMC) from patients
(n = 12) and from control subjects (n = 9) with RT-PCR. IL-18 and IL-10 serum protein levels were measured using ELISA.
BAL cells and PBMC of CF patients expressed significantly less IL-18 compared to controls ( p < 0.05). There was no significant
difference for IL-10 in BAL cells. However, PBMC from patients expressed significantly more IL-10 mRNA ( p < 0.05). IL-18 serum protein
levels were decreased in the patient group, whereas IL-10 serum concentrations were elevated. Stimulation with rhIL-10 reduced IL-18
expression in PBMC from CF patients.
Decreased IL-18 expression in CF patients may contribute to decreased IFN-g production. IL-10 may contribute to inhibit IL-18
expression in PBMC in CF.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Expression interleukin-18; Interleukin-10; Interferon-g1. Introduction
A primary dysregulation of pulmonary inflammation
with a relative defect in Th1 immune response has been
proposed as a mechanism leading to airways disease in
cystic fibrosis (CF) [1]. Peripheral blood lymphocytes
from CF patients produce significant lower levels of the
Th1 cytokine interferon-g (IFN-g) upon stimulation com-
pared to control lymphocytes [2]. Since interleukin-18 (IL-
18) induces IFN-g production [3] we sought to investigate
the expression of IL-18 and IL-10 (as IL-18 inhibiting
factor) in the lungs and peripheral blood of adult CF
patients.1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.03.006
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2.1. Patients and control subjects
Twelve adult CF patients were investigated (5 male, 7
female, mean age 28.3 years ranging form 23 to 39).
Pseudomonas aeruginosa was found in sputum cultures of
all CF patients. Nine healthy non-smoking volunteers served
as control group (4 male, 2 female, mean age 27.4 years
ranging from 23 to 31).
2.2. Bronchoalveolar lavage and blood samples
Bronchoalveolar lavage (BAL) was performed in five
patients and in all control subjects. Peripheral blood samples
of all patients and control subjects were obtained for serum
and peripheral blood mononuclear cells (PBMC).
2.3. RT-PCR and semiquantitative PCR analysis
RNA preparation, reverse transcription and PCR were
performed as previously described [4]. The oligonucleotideed by Elsevier B.V. All rights reserved.
Fig. 1. Semiquantitative PCR analysis of IL-18 mRNA (A) and IL-10
mRNA (B) expression in BAL cells and PBMC of patients and control
subjects. Columns represent mean values ( + S.E.M.). *p< 0.05 vs. control.
Fig. 2. Effect of IL-10 stimulation on PBMC of patients. Columns represent
mean values ( + S.E.M.) of semiquantitative PCR analysis. *p< 0.05 vs.
unstimulated.
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published before [5,6]. PCR products were analyzed, den-
sitometric analysis and semiquantitative RNA quantification
was performed as previously described [4].
2.4. Interleukin-18 and interleukin-10 enzyme-linked
immuno-sorbent assay
An IL-18 enzyme-linked immuno-sorbent assay
(ELISA) (R&D Systems, Minneapolis, USA) was used
to determine the concentration of IL-18 in the sera of
both groups and PBM cell culture supernatants of
patients. An IL-10 ELISA (R&D Systems) was used to
determine the concentration of IL-10 in sera of both
groups. Minimum detectable doses were less than 15
pg/ml (IL-18) and less than 3.9 pg/ml (IL-10) as indicated
by the manufacturer.
2.5. Stimulation of PBMC with recombinant human IL-10
PBMC from four patients were cultured in RPMI
medium without and in the presence of 0.4 Ag/mlrecombinant human (rh) IL-10 as indicated by the man-
ufacturer (Strathmann Biotech, Hannover, Germany). IL-
18 mRNA expression and IL-18 protein levels in cell
culture supernatants were determined after 18 h.
2.6. Statistics
IL-18 and IL-10 expression as well as IL-18 and IL-10
serum protein levels between patients and control subjects
were compared using the Mann–Whitney U-test. IL-18
expression without and in the presence of rhIL-10 was
compared with the paired t-test. A P value of less than
0.05 was considered significant. All values are given as
meanF S.E.M. if not otherwise stated.3. Results
3.1. Expression of IL-18 and IL-10 MRNA in BAL cells and
PBMC
BAL cells of investigated patients (n = 5) expressed
significantly less IL-18 mRNA compared to controls
(1.44F 0.80 vs. 3.68F 0.53; p < 0.05). IL-18 mRNA ex-
pression was significantly lower in PBMC of patients
compared to PBMC of control subjects (0.41F 0.09 vs.
1.59F 0.55; p < 0.05) (Fig. 1A).
IL-10 mRNA expression in BAL cells was very low in
both groups (0.02F 0.02 vs. 0.01F 0.01, p>0.05). PBMC
of patients expressed significantly more IL-10 mRNA in
comparison with control subjects (0.73F 0.24 vs. < 0.01;
p < 0.05) (Fig. 1B).
3.2. IL-18 and IL-10 serum protein levels
Eight patients and eight control subjects had detectable
IL-18 serum protein levels. The median level of patients
was lower than that of control individuals (42.91 pg/ml
vs. 74.78 pg/ml; p>0.05). While IL-10 serum protein
levels were below minimum detectable dose in all control
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protein concentrations with a median value of 8.38 pg/ml
( p < 0.05).
3.3. Effect of stimulation with rhIL-10 on IL-18
Stimulation with rhIL-10 significantly reduced IL-18
mRNA expression in PBMC of patients compared to
without stimulation (0.46F 0.11 vs. 0.89F 0.19; p < 0.05)
(Fig. 2). IL-18 protein levels were detectable in only one
patient but stimulation with rhIL-10 decreased protein
concentrations (12.87 pg/ml) in comparison to without
(16.47 pg/ml).4. Discussion
Reduced IL-18 protein levels have been shown in BAL
fluid of CF children [7] but expression in BAL cells and
PBMC of adult patients have not been investigated yet. In
the present study, we found decreased IL-18 expression in
both BAL cells and PBMC of CF patients compared to
control subjects. In that previous study an IL-18 degrading
factor has been postulated to be present in CF BAL fluid [7].
Since P. aeruginosa was found in sputum cultures of the
patients it is tempting to speculate that P. aeruginsa exo-
toxin A may decrease IL-18 expression in BAL as shown in
lungs of mice [8].
IL-10 is known to inhibit IL-18 mRNA expression [9]. In
BAL cells of patients and controls IL-10 was very low. This
agrees with previous data [10]. However, IL-10 expression
in PBMC (as shown before, ref. 2) and IL-10 serum
concentrations in patients were increased. Moreover, stim-
ulation of patient PBMC with rhIL-10 significantly de-
creased IL-18 expression. Therefore IL-10 may inhibit IL-
10 in CF PBMC thus decreasing IFN-g production.5. Conclusions
Increased IL-10 expression in PBMC may inhibit IL-18
expression in PBMC of CF patients. Other factors (e. g. P.aeruginosa exotoxin A) than IL-10 may decrease IL-18 in
CF BAL cells. Decreased IL-18 expression in adult CF
patients may reduce IFN-g production which may lead to a
relative defect in Th1 immune response.Acknowledgements
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